House FDA drug reform bill may be most viable to patient groups -- AIDS patient rep.
This article was originally published in The Tan Sheet
HOUSE FDA DRUG REFORM BILL POTENTIALLY MORE ACCEPTABLE TO PATIENTS GROUPS than the Senate FDA reform legislation, AIDS Action Council representative Gary Rose indicated July 2. At a press conference organized with Public Citizen, representatives of the American Foundation for AIDS Research, AIDS Action Council, the National Organization for Rare Disorders and the National Council on Aging criticized the recently filed committee report on Sen. Nancy Kassebaum's (R-Kan.) FDA reform proposal (S 1477).
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC